创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology: PBMC-T Platform

  • Categories:Company news
  • Author:InnoModels Biotechnology
  • Origin:InnoModels Biotechnology
  • Time of issue:2024-01-22 15:40
  • Views:

(Summary description)The PBMC-T platform from InnoModels Biotechnology is an innovative technology leading the way in biomedical research, designed to deliver highly efficient T-cell products and provide excellent tools and resources to support researchers in the fields of immunotherapy, cancer research, and infectious diseases, among others

InnoModels Biotechnology: PBMC-T Platform

(Summary description)The PBMC-T platform from InnoModels Biotechnology is an innovative technology leading the way in biomedical research, designed to deliver highly efficient T-cell products and provide excellent tools and resources to support researchers in the fields of immunotherapy, cancer research, and infectious diseases, among others

  • Categories:Company news
  • Author:InnoModels Biotechnology
  • Origin:InnoModels Biotechnology
  • Time of issue:2024-01-22 15:40
  • Views:
Information

The PBMC-T platform from InnoModels Biotechnology is an innovative technology leading the way in biomedical research, designed to deliver highly efficient T-cell products and provide excellent tools and resources to support researchers in the fields of immunotherapy, cancer research, and infectious diseases, among others.
1. Efficient T-cell production technology: The PBMC-T platform utilizes advanced cell culture and expansion technologies to ensure that T-cells derived from human Peripheral Blood Mononuclear Cells (PBMCs) have a high degree of activity and functional integrity.
2. Wide range of applications: The products of the PBMC-T platform have a wide range of applications in a variety of research fields, including immunotherapy, cancer research, and infectious diseases. Researchers can utilize these highly efficient T cells for in vitro experiments, drug screening, disease modeling, etc.
3. Customized services: InnoModels Biotechnology provides customized services, offering different types and quantities of T cells according to customers' specific needs to meet the requirements of various research projects. This flexibility enables researchers to obtain personalized solutions that meet their experimental needs.

 


4. Strict Quality Control: InnoModels Biotechnology carries out strict quality control of its PBMC-T platform products to ensure that each batch of T cells meets high quality standards. This quality control ensures the reproducibility and reliability of the experiments.
5. Reliable Supply Chain: The production of PBMC-T platform products adopts efficient supply chain management to ensure that customers can obtain the required T cells in a timely manner, and the progress of research will not be affected by supply problems.
By providing high-quality, high-activity T-cell products, InnoModels's PBMC-T platform is committed to advancing scientific research in the fields of immunotherapy and cancer research, and contributing to the discovery of new therapeutic methods and innovations in the field of biomedicine. The wide application of its products will contribute to an in-depth understanding of the mechanism of action of the immune system and provide important support for disease treatment and prevention.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司